Comprehensive Stock Comparison
Compare Solventum Corporation (SOLV) vs Healthcare Services Group, Inc. (HCSG) vs AMN Healthcare Services, Inc. (AMN) vs Cross Country Healthcare, Inc. (CCRN) vs Cryo-Cell International, Inc. (CCEL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | HCSG | 7.1% revenue growth vs CCRN's -33.5% |
| Value | AMN | Lower P/E (9.6x vs 67.4x) |
| Quality / Margins | SOLV | 18.7% net margin vs AMN's -3.5% |
| Stability / Safety | CCEL | Beta 0.16 vs AMN's 1.00 |
| Dividends | CCEL | 7.3% yield; SOLV, HCSG, AMN, CCRN pay no meaningful dividend |
| Momentum (1Y) | HCSG | +107.3% vs CCEL's -55.4% |
| Efficiency (ROA) | SOLV | 10.9% ROA vs AMN's -4.6%, ROIC 16.9% vs -3.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Solventum is a healthcare company that develops, manufactures, and commercializes medical solutions across four main segments. It generates revenue primarily from medical surgical supplies (~40% of sales), dental products (~25%), health information systems software (~20%), and purification/filtration technologies (~15%). The company benefits from its established brand recognition and comprehensive product portfolio—spanning from wound care to dental orthodontics—which creates switching costs for healthcare providers.
Healthcare Services Group provides outsourced housekeeping, laundry, and dietary services to nursing homes, retirement communities, and hospitals across the United States. It generates revenue through service contracts with healthcare facilities—primarily from its Housekeeping segment (~70% of revenue) and Dietary segment (~30%)—where it manages entire departments for clients. The company's moat lies in its specialized expertise in healthcare facility operations and its scale as a national provider, which creates switching costs for clients who rely on its integrated service model.
AMN Healthcare is a leading healthcare staffing and workforce solutions company that connects healthcare facilities with temporary and permanent medical professionals. It generates revenue primarily through staffing services—with nurse and allied staffing making up the largest segment—alongside physician placement and technology-enabled workforce management solutions. The company's scale, extensive network of healthcare professionals, and established relationships with thousands of healthcare facilities create significant barriers to entry for competitors.
Cross Country Healthcare is a healthcare staffing and workforce solutions company that provides temporary and permanent placement of clinical professionals. It generates revenue primarily from nurse and allied staffing services — which account for the majority of its business — along with physician staffing and workforce management solutions. The company's competitive advantage lies in its extensive national network and deep healthcare industry expertise, which enables it to efficiently match qualified professionals with healthcare facilities facing staffing shortages.
Cryo-Cell International is a cellular processing and cryogenic storage company that preserves umbilical cord blood and tissue stem cells for family use. It generates revenue primarily from cord blood and cord tissue storage services—charging initial processing fees and annual storage fees—with additional income from selling its PrepaCyte CB processing technology to other storage facilities. The company's competitive advantage lies in its established reputation in the family cord blood banking market, proprietary processing technology, and direct-to-consumer marketing relationships with healthcare providers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
HCSG leads in 2 of 6 categories (Total Returns, Analyst Outlook). CCRN leads in 1 (Valuation Metrics). 2 tied.
Financial Metrics (TTM)
SOLV is the larger business by revenue, generating $8.3B annually — 262.2x CCEL's $32M. SOLV is the more profitable business, keeping 18.7% of every revenue dollar as net income compared to AMN's -3.5%. On growth, HCSG holds the edge at +8.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $8.3B | $1.8B | $2.7B | $1.1B | $32M |
| EBITDAEarnings before interest/tax | $2.9B | $60M | $25M | $360,000 | $6M |
| Net IncomeAfter-tax profit | $1.6B | $40M | -$96M | -$16M | $399,609 |
| Free Cash FlowCash after capex | -$9M | $158M | $242M | $46M | $6M |
| Gross MarginGross profit ÷ Revenue | +53.5% | +12.5% | +28.3% | +20.2% | +77.1% |
| Operating MarginEBIT ÷ Revenue | +26.2% | +2.4% | -2.0% | -1.4% | +13.6% |
| Net MarginNet income ÷ Revenue | +18.7% | +2.2% | -3.5% | -1.4% | +1.3% |
| FCF MarginFCF ÷ Revenue | -0.1% | +8.7% | +8.9% | +4.1% | +19.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.7% | +8.5% | +1.8% | -20.6% | -3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +105.6% | +2.1% | +95.9% | -2.9% | -30.8% |
Valuation Metrics
At 8.4x trailing earnings, SOLV trades at a 88% valuation discount to CCEL's 67.4x P/E. On an enterprise value basis, SOLV's 7.8x EV/EBITDA is more attractive than CCRN's 319.8x.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| Market CapShares × price | $12.9B | $1.7B | $987M | $281M | $27M |
| Enterprise ValueMkt cap + debt − cash | $17.0B | $1.6B | $2.1B | $203M | $40M |
| Trailing P/EPrice ÷ TTM EPS | 8.36x | 26.88x | -5.06x | -19.77x | 67.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.54x | 22.54x | 9.57x | 106.36x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.81x | 23.98x | 29.18x | 319.77x | 9.97x |
| Price / SalesMarket cap ÷ Revenue | 1.55x | 0.91x | 0.33x | 0.21x | 0.85x |
| Price / BookPrice ÷ Book value/share | 2.58x | 2.59x | 1.05x | 0.69x | — |
| Price / FCFMarket cap ÷ FCF | — | 12.02x | 4.12x | 2.52x | 7.53x |
Profitability & Efficiency
SOLV delivers a 30.8% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-15 for AMN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.55x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs CCRN's 4/9, reflecting strong financial health.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +30.8% | +8.0% | -14.9% | -3.8% | — |
| ROA (TTM)Return on assets | +10.9% | +4.9% | -4.6% | -2.9% | +0.6% |
| ROICReturn on invested capital | +16.9% | +7.7% | -3.9% | -3.2% | — |
| ROCEReturn on capital employed | +19.0% | +7.8% | -5.0% | -3.4% | +8.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 4 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.00x | 0.03x | 1.55x | 0.01x | — |
| Net DebtTotal debt minus cash | $4.2B | -$116M | $1.1B | -$78M | $12M |
| Cash & Equiv.Liquid assets | $878M | $125M | $11M | $82M | $560,960 |
| Total DebtShort + long-term debt | $5.0B | $19M | $1.1B | $4M | $13M |
| Interest CoverageEBIT ÷ Interest expense | 5.62x | 20.15x | -1.39x | -4.55x | 1.62x |
Total Returns (with DRIP)
A $10,000 investment in SOLV five years ago would be worth $9,275 today (with dividends reinvested), compared to $2,553 for AMN. Over the past 12 months, HCSG leads with a +107.3% total return vs CCEL's -55.4%. The 3-year compound annual growth rate (CAGR) favors HCSG at 17.9% vs AMN's -40.0% — a key indicator of consistent wealth creation.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.1% | +25.5% | +28.8% | +7.9% | -1.7% |
| 1-Year ReturnPast 12 months | -7.0% | +107.3% | -23.1% | -49.3% | -55.4% |
| 3-Year ReturnCumulative with dividends | -7.2% | +64.1% | -78.4% | -67.1% | +5.2% |
| 5-Year ReturnCumulative with dividends | -7.3% | -22.3% | -74.5% | -26.6% | -48.8% |
| 10-Year ReturnCumulative with dividends | -7.2% | -23.5% | -31.5% | -29.9% | +31.2% |
| CAGR (3Y)Annualised 3-year return | -2.5% | +17.9% | -40.0% | -31.0% | +1.7% |
Risk & Volatility
CCEL is the less volatile stock with a 0.16 beta — it tends to amplify market swings less than AMN's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 94.7% from its 52-week high vs CCEL's 42.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 0.74x | 1.00x | 0.43x | 0.16x |
| 52-Week HighHighest price in past year | $88.20 | $22.98 | $27.17 | $17.30 | $7.91 |
| 52-Week LowLowest price in past year | $60.70 | $9.13 | $14.87 | $7.43 | $3.10 |
| % of 52W HighCurrent price vs 52-week peak | +84.1% | +94.7% | +71.7% | +50.3% | +42.6% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 64.3 | 50.8 | 53.2 | 49.7 |
| Avg Volume (50D)Average daily shares traded | 788K | 627K | 1.1M | 490K | 13K |
Analyst Outlook
Analyst consensus: SOLV as "Buy", HCSG as "Buy", AMN as "Buy", CCRN as "Hold". Consensus price targets imply 29.1% upside for SOLV (target: $96) vs 7.2% for HCSG (target: $23). CCEL is the only dividend payer here at 7.30% yield — a key consideration for income-focused portfolios.
| Metric | SOLVSolventum Corpora… | HCSGHealthcare Servic… | AMNAMN Healthcare Se… | CCRNCross Country Hea… | CCELCryo-Cell Interna… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | — |
| Price TargetConsensus 12-month target | $95.80 | $23.33 | $22.88 | $9.93 | — |
| # AnalystsCovering analysts | 11 | 14 | 17 | 13 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +7.3% |
| Dividend StreakConsecutive years of raises | — | 20 | — | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $0.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.7% | 0.0% | +13.3% | +5.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 24 | Feb 26 | Change |
|---|---|---|---|
| Solventum Corporati… (SOLV) | 100 | 96.14 | -3.9% |
| Healthcare Services… (HCSG) | 100 | 153.96 | +54.0% |
| AMN Healthcare Serv… (AMN) | 100 | 34.99 | -65.0% |
| Cross Country Healt… (CCRN) | 100 | 50.05 | -49.9% |
| Cryo-Cell Internati… (CCEL) | 100 | 45.31 | -54.7% |
Solventum Corporati… (SOLV) returned -7% over 5 years vs AMN Healthcare Serv… (AMN)'s -74%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solventum Corporati… (SOLV) | $8.2B | $8.3B | +1.9% |
| Healthcare Services… (HCSG) | $1.6B | $1.8B | +17.6% |
| AMN Healthcare Serv… (AMN) | $1.9B | $3.0B | +56.9% |
| Cross Country Healt… (CCRN) | $834M | $1.3B | +61.2% |
| Cryo-Cell Internati… (CCEL) | $23M | $32M | +38.3% |
Healthcare Services Group, Inc.'s revenue grew from $1.6B (2016) to $1.8B (2025) — a 1.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solventum Corporati… (SOLV) | 17.9% | 18.7% | +4.6% |
| Healthcare Services… (HCSG) | 5.0% | 3.2% | -35.1% |
| AMN Healthcare Serv… (AMN) | 5.6% | -4.9% | -188.5% |
| Cross Country Healt… (CCRN) | 1.0% | -1.1% | -213.3% |
| Cryo-Cell Internati… (CCEL) | -5.7% | 1.3% | +122.0% |
Healthcare Services Group, Inc.'s net margin went from 5% (2016) to 3% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Healthcare Services… (HCSG) | 44.3 | 23.6 | -46.7% |
| AMN Healthcare Serv… (AMN) | 18.4 | 14 | -23.9% |
| Cross Country Healt… (CCRN) | 12.6 | 11 | -12.7% |
| Cryo-Cell Internati… (CCEL) | 32.2 | 148.2 | +360.2% |
Healthcare Services Group, Inc. has traded in a 20x–44x P/E range over 9 years; current trailing P/E is ~27x. AMN Healthcare Services, Inc. has traded in a 10x–46x P/E range over 7 years; current trailing P/E is ~-5x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solventum Corporati… (SOLV) | 8.47 | 8.88 | +4.8% |
| Healthcare Services… (HCSG) | 1.05 | 0.81 | -22.9% |
| AMN Healthcare Serv… (AMN) | 2.15 | -3.85 | -279.1% |
| Cross Country Healt… (CCRN) | 0.15 | -0.44 | -393.3% |
| Cryo-Cell Internati… (CCEL) | -0.16 | 0.05 | +131.3% |
Healthcare Services Group, Inc.'s EPS grew from $1.05 (2016) to $0.81 (2025) — a -3% CAGR.
Chart 6Free Cash Flow — 5 Years
Solventum Corporation generated $-10M FCF in 2025 (-101% vs 2021). Healthcare Services Group, Inc. generated $139M FCF in 2025 (+343% vs 2021).
SOLV vs HCSG vs AMN vs CCRN vs CCEL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SOLV or HCSG or AMN or CCRN or CCEL a better buy right now?
Solventum Corporation (SOLV) offers the better valuation at 8.4x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SOLV or HCSG or AMN or CCRN or CCEL?
On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.4x versus Cryo-Cell International, Inc. at 67.4x. On forward P/E, AMN Healthcare Services, Inc. is actually cheaper at 9.6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SOLV or HCSG or AMN or CCRN or CCEL?
Over the past 5 years, Solventum Corporation (SOLV) delivered a total return of -7.3%, compared to -74.5% for AMN Healthcare Services, Inc. (AMN). A $10,000 investment in SOLV five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CCEL returned +31.2% versus AMN's -31.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SOLV or HCSG or AMN or CCRN or CCEL?
By beta (market sensitivity over 5 years), Cryo-Cell International, Inc. (CCEL) is the lower-risk stock at 0.16β versus AMN Healthcare Services, Inc.'s 1.00β — meaning AMN is approximately 509% more volatile than CCEL relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 155% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — SOLV or HCSG or AMN or CCRN or CCEL?
Solventum Corporation (SOLV) is the more profitable company, earning 18.7% net margin versus -4.9% for AMN Healthcare Services, Inc. — meaning it keeps 18.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26.2% versus -3.4% for AMN. At the gross margin level — before operating expenses — CCEL leads at 75.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SOLV or HCSG or AMN or CCRN or CCEL more undervalued right now?
On forward earnings alone, AMN Healthcare Services, Inc. (AMN) trades at 9.6x forward P/E versus 106.4x for Cross Country Healthcare, Inc. — 96.8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SOLV: 29.1% to $95.80.
07Which pays a better dividend — SOLV or HCSG or AMN or CCRN or CCEL?
In this comparison, CCEL (7.3% yield) pays a dividend. SOLV, HCSG, AMN, CCRN do not pay a meaningful dividend and should not be held primarily for income.
08Is SOLV or HCSG or AMN or CCRN or CCEL better for a retirement portfolio?
For long-horizon retirement investors, Cryo-Cell International, Inc. (CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.16), 7.3% yield). Both have compounded well over 10 years (CCEL: +31.2%, AMN: -31.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SOLV and HCSG and AMN and CCRN and CCEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SOLV is a mid-cap deep-value stock; HCSG is a small-cap quality compounder stock; AMN is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; CCEL is a small-cap income-oriented stock. CCEL pays a dividend while SOLV, HCSG, AMN, CCRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.